Suzhou Singmed Medical Device Science and Technology Ltd. (“Singmed”) has completed a Series B financing round of approximately US$44 million in April.

The round was led by Oriza Seed, with follow-on investment from existing investor Creacion Ventures and new investment from UOB Venture Management Private Limited, Jolmo Capital, Changshu Jingkai Holding Co., Ltd., Changshu Guofa Venture Capital Co., Ltd., and other investors.

Singmed is a Chinese drug delivery technology company with proprietary R&D capabilities across three core areas: dry powder inhalation, soft mist inhalation, and precision nasal drug delivery. The company said the proceeds will be used to further advance its delivery technology platform for innovative therapeutics, with a focus on pulmonary delivery, nasal drug delivery, and other advanced drug delivery applications.

“The future competitiveness of innovative therapeutics will not be defined by the molecule alone,” said Albert Zhao, Chairman of Singmed. “It will increasingly depend on the delivery system, the user experience, and the ability to develop and commercialize globally. What Singmed continues to invest in is not a single device product, but an integrated delivery technology platform built around the needs of innovative drug development.”

Several novel drug programs using Singmed’s dry powder inhalation device have already made clinical progress in both China and the United States, covering indications such as interstitial lung disease and chronic obstructive pulmonary disease, with some having entered breakthrough-designation programs.

The investor base in this round reflects a mix of cross-border capital, market-oriented institutions, and state-backed funds. Dr. Jennie Zang, Investment Director at Oriza Seed, said the firm is backing not a single product, but Singmed’s integrated delivery technology platform, which she believes represents the future. She added that the company has built strong capabilities in device development, precision engineering, and industrialization, and has the potential to become a leading full-spectrum solutions provider for innovative therapeutics and complex drug-device combination products.

Dr. Ching Zhu, Founding Partner of Creacion Ventures, said delivery systems are a strategic anchor for product differentiation, intellectual property positioning, and global development feasibility in complex drug-device combination products. He added that Singmed has demonstrated world-class innovation and engineering capabilities, making it a company worth backing over the long term.

Kian-Wee Seah, Chief Executive Officer of UOB Venture Management Private Limited, said he sees strong potential in Singmed and expects to leverage UOB’s Southeast Asia network to support the company’s regional expansion and accelerate its global rollout.

Haishun Sun, Deputy General Manager of Investment at Jolmo Capital, said Singmed has helped fill a domestic technology gap in drug delivery devices and that the firm will continue to support the company’s long-term development.

About Singmed

Singmed is a Chinese drug delivery technology company focused on dry powder inhalation, soft mist inhalation, and precision nasal drug delivery systems. The company is building integrated delivery platforms for innovative therapeutics, spanning device development, engineering translation, and industrialization, with applications in pulmonary delivery, nasal delivery, and other advanced drug delivery fields.

Company：Suzhou Singmed Medical Device Science and Technology Ltd.

Contact Person: Kate Tang

Email: kate.tang@singmed.cn

Website: www.singmed.cn

Telephone: 86-0512-52087280

City：Changshu